GlassScriptPhysician profile
Staci Kies Wise
NPI 1902026800
$1,498.51
in general payments reported to CMS, 2019-2025
26 companies · $38.75 in 2025
The $38.75 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,357 · 2022: $103 · 2025: $38.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $38.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $38.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $174.55 | 2021 | |
| Lilly USA, LLC | $167.93 | 2021 | |
| Tandem Diabetes Care, INC. | $126.96 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $118.03 | 2021-2022 | |
| Corcept Therapeutics | $81.96 | 2021 | |
| Merck Sharp & Dohme LLC | $69.56 | 2021 | |
| Zealand Pharma US, INC. | $68.43 | 2021 | |
| Esperion Therapeutics, INC. | $67.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.39 | 2021 | |
| Amgen INC. | $64.69 | 2021 | |
| Insulet Corporation | $62.94 | 2021 | |
| Dexcom, INC. | $61.22 | 2021 | |
| Antares Pharma, INC. | $60.81 | 2021 | |
| Abbvie INC. | $59.55 | 2021 | |
| Abbott Laboratories | $38.75 | 2025 | Freestyle Libre |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $37.64 | 2021 | |
| Ibsa Pharma INC. | $31.76 | 2021 | |
| Currax Pharmaceuticals LLC | $23.80 | 2021 | |
| Cequr Corporation | $20.12 | 2021 | |
| Medtronic, INC. | $15.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.17 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.34 | 2021 | |
| Grt US Holding, INC. | $13.31 | 2021 | |
| Pfizer INC. | $13.13 | 2021 | |
| Amarin Pharma, INC. | $12.75 | 2021 | |
| Mannkind Corporation | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.